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The Abacavir Trial in Context
HIV-associated dementia (HAD) and
milder forms of cognitive impairment
produce a spectrum of disability that
ranges from complete inability to care
for oneself to reduced work efﬁciency and
quality of life. HAD is believed to arise
from a conﬂuence of adverse effects on
neuronal function resulting both from
HIV itself and from disturbances in
cellular signalling, particularly in the
immune system, that further damage
neurons. More than two decades after
the recognition of HAD as a clinical
entity, guidelines for antiretroviral drug
treatment in people with HAD and
cognitive impairment have yet to be
established. The study reported in PLoS
Clinical Trials by Brew et al. [1] was
designed to help develop such guidelines
by testing whether adding a single ‘‘neu-
roactive’’ antiretroviral, abacavir, to an
existing regimen would beneﬁt brain
function in patients with dementia. Aba-
cavir is a potent inhibitor of HIV reverse
transcriptase that interferes with the viral
lifecycle and shows reasonably good
penetration into central nervous system
(CNS) tissues. The trial was historically
important because it was done at a pivotal
time in the development of antiretroviral
therapy, as potent combination drug
regimens including protease inhibitors
emerged into widespread use in the
United States, Europe, and Australia.
The rationale for the study was simple
and transparent. It was anticipated that
this ‘‘CNS active’’ agent would suppress a
potential reservoir of HIV in the central
nervous system, where other drugs, espe-
cially protease inhibitors, might not be
effective. At the time this study was
designed, a number of important scientiﬁc
observations about HAD and its treatment
had been made. Zidovudine, the earliest
available nucleoside reverse transcriptase
inhibitor, seemed to improve the motor
functions of people with HAD when given
in higher doses than normally used for
treatment of systemic HIV disease [2].
Additionally, observational data showed
that dementia prevalence in the West
dropped after zidovudine became avail-
able, suggesting that zidovudine prevented
HAD [3,4]. Even so, the burden of mild
cognitive impairment in HIV remained
substantial [5–7].
The trial was historically
important because it
was done at a pivotal
time in the development
of antiretroviral therapy.
What Has Been Learnt Since This Trial
Was Conducted?
Although the trial reported here [1] was
completed in January 1998, publication
was delayed for several years. In the years
between completion and publication of
the trial, knowledge about the impact of
antiretroviral therapy on cognitive im-
pairment in HIV continued to accumu-
late. New cases of severe dementia
became less frequent [8,9], and there was
clear evidence of improved cognitive
function, even in those with mild impair-
ment [10]. Immunity improved and lon-
gevity increased in surviving patients with
dementia and mild cognitive impairment.
This increase in survival was particularly
dramatic for individuals with frank de-
mentia: in the era before highly active
antiretroviral therapy (HAART), average
survival was about ﬁve months, whereas in
the HAART era it is close to 40 months
[11]. However, many affected individuals
did not fully recover their baseline
cognitive abilities. Thus, the prevalence
of cognitive impairment gradually in-
creased [12] and it became more common
in persons with higher CD4 counts
[12,13]. Finally, evidence emerged, albeit
not unanimous, that cognitive recovery
was greatest in those who received
antiretroviral medications with better
CNS penetration characteristics and in
those who fully suppressed viral load in
cerebrospinal ﬂuid [14].
Findings of the Abacavir Trial
In this randomized, double-blind, place-
bo-controlled trial, 105 HIV-positive pa-
tients with HAD who were already
receiving combination antiretroviral reg-
imens (‘‘stable background therapy’’
[SBG]) for at least eight weeks were
randomized to treatment with abacavir
or placebo for 12 weeks, in addition to
their existing regimen. Patients in both
treatment arms improved substantially,
with the median change in a composite
neuropsychological performance index
(NPZ) at week 12 exceeding one half of
a standard deviation. Improvement was
slightly, but not statistically signiﬁcantly
better in the abacavir-treated patients
than in those receiving placebo.
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Limitations
A strength of this study is that it is one of
very few prospective, randomized,
blinded comparative trials for HAD. The
study was well-designed and the agent, a
newly developed, potent, nucleoside re-
verse transcriptase inhibitor with favor-
able pharmacological and tolerability
characteristics and predicted good CNS
penetration, was of great interest. The
targeted patient group was clearly de-
ﬁned and had received relatively little
attention in prior antiretroviral treat-
ment studies, offering the potential for
this study to have a substantial impact on
prescribing practices. However, the
study’s ability to fulﬁll its goals was
substantially limited by several factors,
including rapid new developments in
antiviral treatment for HIV.
First, although referred to as ‘‘optimal’’
background therapy, participants’ regi-
mens at trial entry were for the most part
failing, with virologic success (undetect-
able plasma viral load) having been
achieved in only 23% of individuals in
the abacavir arm, and 9% of individuals
in the placebo arm. This lack of virologic
efﬁcacy of SBG may have reﬂected a
variety of contributing factors, including
drug resistance, poor adherence to ART
resulting from cognitive impairment, and
the relative inexperience of practitioners
at that time in applying combination
regimens. Additionally, since access to
abacavir was restricted at the time the
study was being performed, it is possi-
ble—even likely—that referral of patients
to this study was biased towards those
who were failing their existing regimens
and therefore in need of a new agent.
Second, although the investigators
could not have known it at the time, single
agent add-on therapy was subsequently
shown to be largely ineffective. Antire-
troviral treatment guidelines released
after the trial began clearly indicate that,
for ART-treated individuals with emerg-
ing virologic failure (detectable plasma
viral load) and suspected drug resistance,
providers should change at least two drugs
in the regimen to active agents [15]. Thus
the main intervention of this study, add-
ing a single agent to an existing, failing
antiretroviral regimen, was in retrospect
not a viable treatment strategy.
Virologic suppression from baseline to
12 weeks improved somewhat more in the
abacavir group (23% to 46%) than in the
placebo arm (9% to 13%). Brew et al. [1]
interpret this as demonstration of the
virologic efﬁcacy of abacavir add-on
therapy. However, the median baseline
viral load for the abacavir group (3.7 log10
c/ml) was substantially closer to the assay
detection limit (2.6 log10 c/ml) than for
the placebo group (4.6 log10 c/ml). By way
of contrast, effective, modern combina-
tion regimens achieve virologic suppres-
sion in more than two thirds of patients
over 12 weeks, and frequently produce
viral load declines of 2–3 logs [16]. Addi-
tional evidence of the limited potency of
abacavir versus placebo was provided by
the lack of CD4 response in both groups.
Individuals with CD4 counts comparable
to those in this study frequently show
substantial CD4 beneﬁt with effective
ART. Since abacavir had a very modest
effect on the virus, and virtually none on
immunity, its effects on brain function
may have been so modest as to elude
detection by neuropsychological testing.
The abacavir trial has
taught us several
important lessons.
This issue is of particular importance
since most of the individuals in this study
had mild or moderate, rather than severe
cognitive impairment. While the clinical
signiﬁcance of mild cognitive impairment
is clear in relation to Alzheimer disease,
where early intervention may prevent or
delay the onset of frank dementia, its
relationship to dementia in HIV-positive
patients is less clear. In HIV, mild
cognitive impairment does not predict-
ably progress to dementia. Therefore, to
demonstrate efﬁcacy, therapies need to be
more potent, more patients need to be
studied, or both.
One possible explanation for the lack of
difference between the abacavir and
placebo patients is that there was a large
practice effect in both groups; that is,
patients took the same tests repeatedly,
givingthemtheopportunitytobettertheir
performance with practice, independent
of any improvement in brain function. If
practice effects were large in both treat-
ment groups, their magnitude might have
obscured any incremental improvement
related to the hypothesized beneﬁcial
effect of abacavir on brain function. Brew
et al. [1] argue that this explanation is
unlikely. However, the fact that the tests
were administered twice (baseline, week 6)
beforethetimepointatwhichtheprimary
outcome was measured (week 12) gave
participants ample opportunity to beneﬁt
from practice. Other clinical trials with a
similar design have also found substantial
improvementswithinindividualsrandom-
ized to the placebo arm over the course of
the trial [17].
Another potential reason for the lack
of superiority of abacavir was that
patients in both groups were continuing
to experience improvement related to
their initial ART (SBG), independent of
the study intervention. Similar to practice
effects, the argument here is that the
magnitude of this improvement in all
subjects related to SBG overwhelmed any
additional incremental beneﬁt related to
abacavir itself. However, if both groups
were still beneﬁting substantially from
the introduction of their prior antiretro-
viral regimens, then it should have been
possible to demonstrate a graded effect,
with improvements being greatest in
those who started their background
regimens more recently and least in those
whose background regimens had been
started more remotely. Unfortunately,
information about the duration of ther-
apy prior to study enrollment is not
provided in the article, so this possibility
cannot be adequately evaluated.
Implications for Clinical Practice,
Research, Health Policy, and the
Future of HIV Neurotherapeutics
The abacavir trial has taught us several
important lessons. First, since potent,
combination systemic ART is available it
is no longer acceptable to design trials of
single antiretroviral agents. Instead, we
need to design trials using combination
antiretroviral therapies, and clinical tria-
lists need to anticipate emerging develop-
ments in ART and plan for their impact.
We need to improve the sensitivity and
speciﬁcity of methods for measuring
neurocognitive change over time. For
e x a m p l e ,t h eR e l i a b l eC h a n g eI n d e x
represents a methodologically rigorous
means of identifying meaningful neuro-
psychological performance improvement
in individual participants [18]. Scores
above a statistically speciﬁed conﬁdence
interval are interpreted as improvement
beyond what would be expected based on
normal variability and practice effects.
We need to better understand the natural
history and interrelationships of demen-
tia and milder forms of neurocognitive
impairment. Finally, clinically useful pre-
dictive and surrogate markers might help
to conduct controlled clinical trials rap-
idly, and with large enough numbers to
impact practice. “
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